Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.

Esketamine for treatment resistant depression

Abstract

Introduction : Treatment Resistant Depression (TRD) is a common and burdensome condition with poor outcomes and few treatment options. Esketamine is the S-enantiomer of ketamine and has recently been FDA approved in the United States for treating depression that has failed to respond to trials of two or more antidepressants. Areas covered : This review will briefly discuss current treatment options for TRD, then review esketamine. Relevant literature was identified through online database searches, and clinical trial data were provided by Janssen Pharmaceuticals. Pharmacology, including kinetics and dynamics, is discussed, then clinical data regarding efficacy and safety for esketamine from Phase 2-3 trials are reviewed. Expert opinion : In the expert opinion, the authors discuss multiple factors including patient, physician, and social factors that will influence the use of esketamine. While the efficacy of esketamine compared to off-label use of racemic ketamine remains unclear, both esketamine's approval for use in TRD and longer-term safety data may position it preferentially above racemic ketamine, although factors such as cost and monitoring requirements may limit its use. While questions remain regarding duration and frequency of treatment, as well as addictive potential, esketamine is a novel treatment option offering new hope for TRD.

Overview

Integrity signals

Registry

Crossref · 10.1080/14737175.2019.1640604

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 104 references

Research works printed but not linked: 3

  1. Janssen Pharmaceuticals inc, 2019, SpravatoTM (esketamine hydrochloride) [Package insert]
  2. 10.1046/j.1440-1614.2002.01026.x · doi:10.1046/j.1440-1614.2002.01026.x
  3. Chu PS-K, BJU Int, 2008

Cited by

See all 168

Metadata

Authors
Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L.
Affiliations
  • University of Alberta (CA)
  • Weihai City Mental Health Center (CN)
Corresponding author
Swainson, Jennifer
Venue
Expert Review of Neurotherapeutics
Published
2019-07-16
Volume
19
Issue
10
Pages
899-911
ISSN
  • 1473-7175 (ISSN-L)
  • 1744-8360
OpenAlex
W2959816154
Cited by
151
References
104
Citations by year
2026: 9 · 2025: 32 · 2024: 30 · 2023: 19 · 2022: 24 · 2021: 21 · 2020: 12 · 2019: 3
FWCI
9.45
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Review of Neurotherapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
not funded
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
esketamine, treatment-resistant depression, ketamine, antidepressant efficacy, drug safety, pharmacokinetics, pharmacodynamics, off-label drug use, addiction potential, long-term safety
MeSH terms
Antidepressive Agents, Humans, Ketamine, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Esketamine for treatment resistant depression. https://app.cochat.ai/papers/10.1080/14737175.2019.1640604
The paper
Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L. (2019). Esketamine for treatment resistant depression. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2019.1640604

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.